Skip to content

Epidural Morphine Versus Epidural Fentanyl Infusion Following Cesarean Section

A Comparison of Single Dose Preservative Free Morphine With Fentanyl Infusion for Post-Cesarean Section Analgesia

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01362998
Enrollment
2
Registered
2011-06-01
Start date
2011-01-31
Completion date
2012-06-30
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

fentanyl, morphine, duramorph, Cesarean section, epidural

Brief summary

For post-Cesarean analgesia, the investigators will compare the efficacy of single-shot epidural preservative free morphine with a continuous epidural fentanyl infusion. The investigators will be comparing the patient's pain level and satisfaction with the two techniques, as well as the side effects that the patients experience, such as itching, nausea, back pain and respiratory depression.

Detailed description

Included in the study will be all healthy (ASA I or II) woman having elective Cesarean sections who are candidates for regional anesthesia. Exclusion criteria include morbid obesity (BMI \> 40), age less that 18 years, history of sleep apnea, and abuse of or intolerance to opioid analgesics. All patients will also receive 100 micrograms of fentanyl once epidurally during the Cesarean section, and they will receive ibuprofen every six hours for the first 24 hours after the Cesarean section. The patients will be visited twice a day postoperatively for two days. The epidural morphine will be expected to last only approximately 20 hours, while the fentanyl infusion will be kept in place for two days after the procedure. Additional analgesics, such as intravenous morphine or PO oxycodone and tylenol, will be available for breakthrough pain.

Interventions

3mg given epidurally during the Cesarean section.

DRUGFentanyl

An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.

Sponsors

Goodman, Evan, M.D.
Lead SponsorINDIV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients having an elective Cesarean section * Healthy women (ASA I or II) * Regional anesthesia candidates

Exclusion criteria

* Morbid obesity (BMI\>40) * Sleep apnea * Age under 18 * Intolerance or addiction to opioids

Design outcomes

Primary

MeasureTime frameDescription
Postsurgical PainAt 8, 24 36 and 48 hours after the Cesarean sectionParticipants will be asked to rate their pain on a 10 point Numerical Rating Pain Scale, where zero is no pain and ten is the most intense pain possible.

Secondary

MeasureTime frameDescription
Number of Participants Who Responded Yes to Having Nausea or VomitingAt 8, 24, 36 and 48 hours after the Cesarean sectionThe patient will be asked whether she has nausea or vomiting (yes=1, no=0).
Patient SatisfactionAt 8, 24, 48 and 36 hours after Cesarean sectionParticipants will be asked to rate their satisfaction on a 10 point Numerical Rating Scale (0=worst, 10=best).
Number of Participants Who Responded Yes to Having Back PainAt 8, 24, 36 and 48 hours after the Cesarean sectionParticipants will be asked whether they have back pain (Yes=1, No=0)
Number of Participants Who Were Observed by Their Nurse to Have Urinary RetentionAt 8, 24, 36 and 48 hours after Cesarean sectionParticipant's nurse will be asked whether \>400ml was obtained by straight cath (Y=1, No=0)
Number of Participants Who Were Observed by Their Nurse to Have Respiratory DepressionAt 8, 24, 36 and 48 hours after the Cesarean sectionParticipant's chart will be examined to determine whether the respiratory rate was \<8 per minute (Yes=1, No=0)
Number of Participants Who Responded Yes to Having PruritisAt 8, 24, 36 and 48 hours after Cesarean sectionParticipants will be asked whether they have pruritis (Yes=1, No=0)

Other

MeasureTime frameDescription
Number of Participants Who Required Additional Pain MedicationsAt 8, 24, 36 and 48 hours after the Cesarean sectionParticipant's nurse will be asked whether the patient required additional pain medications (Yes=1, No=0)

Countries

United States

Participant flow

Recruitment details

2 people were recruited for this study, but data was collected for only one of them.

Participants by arm

ArmCount
Preservative Free Morphine
This group will receive 3mg of preservative free morphine epidurally during the procedure. Preservative free morphine: 3mg given epidurally during the Cesarean section.
0
Fentanyl Infusion
This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days. Fentanyl: An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
1
Total1

Baseline characteristics

CharacteristicFentanyl InfusionTotalPreservative Free Morphine
Age, Continuous27 Years27 Years
Gestational age, continuous39 Weeks39 Weeks
Pregnancies, integer4 Number of pregnancies4 Number of pregnancies
Sex: Female, Male
Female
1 Participants1 Participants0 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Weight, continuous179 pounds179 pounds

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 1
other
Total, other adverse events
0 / 00 / 1
serious
Total, serious adverse events
0 / 00 / 1

Outcome results

Primary

Postsurgical Pain

Participants will be asked to rate their pain on a 10 point Numerical Rating Pain Scale, where zero is no pain and ten is the most intense pain possible.

Time frame: At 8, 24 36 and 48 hours after the Cesarean section

Population: No participants in morphine arm.

ArmMeasureGroupValue (NUMBER)
Fentanyl InfusionPostsurgical Pain8 hours post Cesarean section3 Units on a 10 point scale
Fentanyl InfusionPostsurgical Pain24 hours post Cesarean0 Units on a 10 point scale
Fentanyl InfusionPostsurgical Pain36 hours post Cesarean3 Units on a 10 point scale
Fentanyl InfusionPostsurgical Pain48 hours post Cesarean7 Units on a 10 point scale
Secondary

Number of Participants Who Responded Yes to Having Back Pain

Participants will be asked whether they have back pain (Yes=1, No=0)

Time frame: At 8, 24, 36 and 48 hours after the Cesarean section

Population: No participants in the morphine arm.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Back Pain8 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Back Pain24 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Back Pain36 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Back Pain48 hours after the surgery0 Participants
Secondary

Number of Participants Who Responded Yes to Having Nausea or Vomiting

The patient will be asked whether she has nausea or vomiting (yes=1, no=0).

Time frame: At 8, 24, 36 and 48 hours after the Cesarean section

Population: No patients were in the morphine group

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Nausea or Vomiting8 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Nausea or Vomiting24 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Nausea or Vomiting36 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Nausea or Vomiting48 hours after the surgery0 Participants
Secondary

Number of Participants Who Responded Yes to Having Pruritis

Participants will be asked whether they have pruritis (Yes=1, No=0)

Time frame: At 8, 24, 36 and 48 hours after Cesarean section

Population: No participants in the morphine arm.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Pruritis48 hours after the surgery1 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Pruritis8 hours after the surgery1 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Pruritis24 hours after the surgery1 Participants
Fentanyl InfusionNumber of Participants Who Responded Yes to Having Pruritis36 hours after the surgery1 Participants
Secondary

Number of Participants Who Were Observed by Their Nurse to Have Respiratory Depression

Participant's chart will be examined to determine whether the respiratory rate was \<8 per minute (Yes=1, No=0)

Time frame: At 8, 24, 36 and 48 hours after the Cesarean section

Population: No participants in morphine arm.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Respiratory Depression8 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Respiratory Depression24 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Respiratory Depression36 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Respiratory Depression48 hours after the surgery0 Participants
Secondary

Number of Participants Who Were Observed by Their Nurse to Have Urinary Retention

Participant's nurse will be asked whether \>400ml was obtained by straight cath (Y=1, No=0)

Time frame: At 8, 24, 36 and 48 hours after Cesarean section

Population: No participants in morphine arm

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Urinary Retention8 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Urinary Retention24 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Urinary Retention36 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Were Observed by Their Nurse to Have Urinary Retention48 hours after the surgery0 Participants
Secondary

Patient Satisfaction

Participants will be asked to rate their satisfaction on a 10 point Numerical Rating Scale (0=worst, 10=best).

Time frame: At 8, 24, 48 and 36 hours after Cesarean section

Population: There were no participants in the morphine arm.

ArmMeasureGroupValue (NUMBER)
Fentanyl InfusionPatient Satisfaction8 hours after the surgery10 score on a scale
Fentanyl InfusionPatient Satisfaction24 hours after the surgery10 score on a scale
Fentanyl InfusionPatient Satisfaction36 hours after the surgery10 score on a scale
Fentanyl InfusionPatient Satisfaction48 hours after the surgery10 score on a scale
Other Pre-specified

Number of Participants Who Required Additional Pain Medications

Participant's nurse will be asked whether the patient required additional pain medications (Yes=1, No=0)

Time frame: At 8, 24, 36 and 48 hours after the Cesarean section

Population: No participants in morphine arm.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Fentanyl InfusionNumber of Participants Who Required Additional Pain Medications8 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Required Additional Pain Medications24 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Required Additional Pain Medications36 hours after the surgery0 Participants
Fentanyl InfusionNumber of Participants Who Required Additional Pain Medications48 hours after the surgery1 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026